Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
Takeda Pharmaceutical CEO Christophe Weber tried to allay concerns about the company’s planned £46 billion Shire takeover at the annual general meeting on June 28, grilled by shareholders who questioned its debt repayment plan and how it could book profits…
To read the full story
Related Article
- Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
June 6, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…